GlassScriptPhysician profile
Todd Shinnick
NPI 1497727606
$4,712.84
in general payments reported to CMS, 2019-2025
32 companies · $370 in 2025
The $370 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,108 · 2020: $928 · 2021: $1,091 · 2022: $665 · 2023: $275 · 2024: $276 · 2025: $370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $922.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $921.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,276.54 | 2019-2025 | Breztri, Airsupra |
| Amarin Pharma, INC. | $812.58 | 2019-2022 | |
| Abbvie INC. | $639.52 | 2019-2024 | Rinvoq, Qulipta |
| Novartis Pharmaceuticals Corporation | $314.99 | 2019-2022 | |
| Genentech USA, INC. | $197.48 | 2019-2021 | |
| Allergan, INC. | $195.43 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $179.61 | 2019-2022 | |
| Glaxosmithkline, LLC. | $143.05 | 2019-2021 | |
| Astellas Pharma US INC | $130.51 | 2019-2021 | |
| Scpharmaceuticals INC. | $125.00 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $80.32 | 2021-2022 | |
| Eisai INC. | $59.21 | 2021 | |
| Corcept Therapeutics | $57.70 | 2019-2020 | |
| Novo Nordisk INC | $57.22 | 2021 | |
| Amgen INC. | $50.41 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $43.85 | 2019-2020 | |
| Abbott Laboratories | $39.59 | 2019-2021 | |
| Pfizer INC. | $27.96 | 2019 | |
| Edwards Lifesciences Corporation | $27.07 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $24.13 | 2019 | |
| Boston Scientific Corporation | $24.06 | 2019 | |
| Esperion Therapeutics, INC. | $23.86 | 2020 | |
| Ibsa Pharma INC. | $23.69 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.63 | 2021 | |
| Optinose US, INC. | $20.08 | 2022 | |
| Biogen, INC. | $19.85 | 2021 | |
| Lilly USA, LLC | $19.80 | 2023 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.45 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.00 | 2022 | |
| Lucid Diagnostics INC. | $15.18 | 2022 | |
| Hologic Sales and Service, LLC | $14.76 | 2019 | |
| Akcea Therapeutics, INC. | $14.31 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Shinnick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.